Screening for HIV in primary care is cost effective and should be promoted, say researchers General practice-based HIV screening is an important public health intervention which should be used more widely, according to a study led by researchers at Queen Mary University of London and the London School of Hygiene and Tropical Medicine…
FDA approves drug to reduce risk of HER2-positive breast cancer returning The US Food and Drug Administration (FDA) has approved neratinib (Nerlynx; Puma Biotechnology) as the first extended adjuvant therapy for early-stage, HER2-positive breast cancer.…
An aspirin before bed reduces risk of pre-eclampsia in pregnant women Low-dose aspirin taken each night before bed significantly reduces the risk of pre-eclampsia in pregnant women, according to research carried out at King’s College London and the University of Exeter.…
Cannabis drug cuts seizures in childhood epilepsy Cannabidiol shows promise in reducing the frequency of convulsive seizures in patients with Dravet syndrome, a rare and severe form of epilepsy.…
Chondroitin sulfate alleviates symptoms in knee osteoarthritis Study shows positive effects of medicine in managing pain and improving mobility in patients with osteoarthritis.…
Bevacizumab as effective as aflibercept for central retinal vein occlusion Bevacizumab is frequently used off-label for treating macular oedema resulting from central retinal vein occlusion (CRVO), despite a lack of supporting data.…
Research funders pledge transparency on trial results Some of the world’s largest research funders have pledged to make all their trial results publicly available, meaning that doctors and other prescribers will be able to make better informed choices.…
Common oral contraceptive pill has negative effect on general well-being An estimated 100 million women use the contraceptive pill, but surprisingly little is known about its effect on overall health.…
Benefit of steroids for sore throat still unclear Using steroids, rather than antibiotics, for sore throat is marginally more effective after 48 hours, according to a randomised controlled trial.…
Midostaurin approved by FDA for newly diagnosed adults with AML The US Food and Drug Administration (FDA) has approved midostaurin (Rydapt; Novartis) for use in combination with chemotherapy by newly diagnosed acute myeloid leukaemia (AML) patients who have the specific gene mutation, FLT3. Midostaurin is a kinase inhibitor that works by blocking several e…